Dieter Peters, born 1956, received his PHD at the University of Dortmund in chemistry. From 1986 to 1996 he worked at Hoechst AG and from 1996 to 2002 at Celanese AG. In 2002 he joined the Grünenthal Group Switzerland as Managing Director. From October 2011 to May 2017 he worked as Head of Global Product Supply and since May 2017 he is the Head of Global Manufacturing. He is an expert in turn arounds and restructuring.
Challenge Your Peers
Operational Excellence in Pharma Manufacturing – Technology, Capacity and Availability management in manufacturing can provide significant advantages to business - HOW?
How can pharma catch up with state of the art management processes, employee involvement and continuous improvement culture that are daily routine in other industries? (Deliverables: Key must haves to accomplish that)
What are you doing in your company to catch up and which benefits have you realized? (Deliverables: Changes you have implemented and your measurable business advantages)
What are you doing to discover the true waste in your processes and become more productive and service oriented? (Deliverables: What barriers did you overcome, what did you find which wasn’t so obvious, what are your most memorable wins)
How do you work with regulatory requirements and departments to realize innovation and mitigate risk? (Deliverables: Examples of change and cooperation with regulatory colleagues to make it happen)
Who is driving innovation and change in your company – what is your role? (Deliverable: Examples to make an Innovation out of an invention)
How do you efficiently connect R&D and Manufacturing? (Deliverables: Example processes and “Best Practice” process)
How do you integrate external manufacturing in established and innovative products manufacturing? (Deliverables: Role model examples and lessons learned from “challenged” cooperation)
The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company.
We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of approx. € 1.4 bn.
Dr. Christian Jurisch is Senior Maintenance Manager of the Parenterals department at Janssen in Schaffhausen. He has more than 20 years of experience in pharmaceutical engineering. He had different functions as head of medical device manufacturing, packaging engineering, utilities and solid manufacturing engineering. Dr. Jurisch gained his masters degree in mechanical engineering at the Technical University of Darmstadt and completed his PhD in engineering at the Technical University of Munich. He started his professional career at Fresenius Kabi in 1996 in the infusion solutions factory in Friedberg and worked later in Uppsala/Sweden where he was head of Technical Department and Packaging Development until he continued his career in Switzerland at Janssen (Cilag AG) in 2002.
IT & Mobile Technologies Drive Change in Pharma Maintenance Practices
Mobile phones for maintenance execution of SAP-PM
Condition based maintenance technologies and batch processes
Use of data historian in process failure analysis and predictive maintenance
Mobile apps – an enabler for smarter maintenance
Who is Janssen? We’re people; more than 35,000, working hard to treat, cure, stop and prevent some of the most devastating and complex diseases of our time — from diabetes and HIV, to Alzheimer’s and cancer.
Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, pulmonary hypertension, cardiovascular and metabolism. We are driven to action by the plight of patients, and we aspire to make a positive impact on their lives. That’s why we never limit the search for new medicines to our own four walls—we’re always looking to work with partners interested in helping us achieve our goals.
We stay focused on the disease areas where we believe we can make the biggest difference — oncology, neuroscience, immunology, infectious diseases & vaccines, and cardiovascular & metabolism. But success for us doesn’t stop in our labs.
The world is our lab, and we wouldn’t be able to achieve our success if it weren’t for our approach to collaboration. We work closely with like-minded people from researchers to governments, healthcare professionals to patient organizations. And we work with them at every stage, from early discovery to market access and patient education. Our experts collaborate with external parties at every stage of our value chain—from early discovery to market access. We seek medical breakthroughs wherever they occur. Whether you’re at a university, a research organization, or another biotech or pharmaceutical company, we want to hear from you.
We are Janssen. We collaborate with the world for the health of everyone in it.
Dirk Schrader is Executive Vice President and Head of Global Technical Operations at Vifor Pharma, the third biggest and fast growing Swiss pharmaceutical company. Dirk joined Vifor Pharma in 2012, coming from Astra Zeneca where he lead the Asia Pacific/Japan Manufacturing & Supply and later their global Lean & Operational Excellence Program. Prior to that he was with Bristol Myers-Squibb as Operations Head Asia Pacific/Japan and at Bayer HealthCare in many different roles in Tech Ops as well as Commercial. 13 of his 25 years in the industry he spent in the Asian region.
Augmented Reality in Real Shop Floor Automation – Increasing efficiency through reducing setup times.
First realized shop floor application of a system using Augmented Reality to drive performance, quality and employee engagement
Strong business case of an application at a packaging line with fast payback
Great experience from gamification brought to the pharma shop floor.
First insights from Proof-of-Concept to a prototype.
Vifor Pharma Group, formerly Galenica Group, is a global speciality pharmaceutical company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions. The company’s goal is to be a global leader in iron deficiency, nephrology and cardio-renal therapies and strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
Vifor Pharma Group consists of Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, its joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
Vifor Pharma has set up this community to share with you news about the company and the current open positions. Sensitive topics, such as discussions about products or treatment options should be addressed privately with your physician. If you are concerned with an adverse event of a drug or a complaint regarding a product, please directly email firstname.lastname@example.org or call +41 79 788 03 09.
Political and religious discussions are not allowed on this site, as well as inflammatory, defamatory and racist comments. If it is believed that the end result of a discussion will be political, religious or contains inappropriate statements the post may be removed.
Case LifeCycle Cleanroom - frontend System PARMESS LUIMESS
Case LifeCycle Instrument Management - global SAP IMTE - CAMA
Challenge Your Peers
From paperless stainless steel production to the facility of the future – How Single-use technology will change the operational work?
What are the requirements of the industry for the facility of the future?
Do we fully understand the impact of single-use technologies?
How can supplier and manufacturer cooperate better?
What does flexibility mean for you?
The value of diagnostics lies in ‘knowing’
Performed on blood, tissue or other patient samples, in vitro diagnostics are a critical source of objective information for improved disease management and patient care.
In modern healthcare, in vitro diagnostics go far beyond simply telling a doctor whether a patient has a certain disease or not. Today, they are an integral part of decision-making along the entire continuum of a patient’s health or disease, enabling physicians to make full use of IVDs along the healthcare value chain.
In vitro diagnostics (IVDs) have long been considered as the “silent champion” of healthcare, influencing over 60 % of clinical decision-making, while accounting for only about 2 % of total healthcare spending.
Diagnostics allows laboratories to be the reliable partners that healthcare professionals need. It empowers doctors to make the right decisions for their patients at the right time; it allows people to have improved control over their health and wellbeing; and it gives payers and policymakers the confidence that they are investing in the right solutions for patients and the future of healthcare.
Modern diagnostics reduces costs by diminishing subsequent health problems, reducing hospitalization and avoiding unnecessary treatment. The future of sustainable healthcare depends on diagnostics.